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Background and purpose: To assess the efﬁcacy of stereotactic ablative radiotherapy (SABR) for the treat-
ment of non-small cell lung cancer (NSCLC) through a systematic review of all relevant publications from
2006 to the present compared to controls treated with surgery. In the absence of Grade I evidence, the
objective outcome data should form the basis for planning future studies and commissioning SABR ser-
vices.
Materials and methods: Standard systematic review methodology extracting patient and disease charac-
teristics, treatment and outcome data from published articles reporting patient data from populations of
20 or more Stage I NSCLC patients treated with SABR with a median follow up of minimum of 1 year. The
individual outcome measures were corrected for stage and summary weighted outcome data were com-
pared to outcome data from a large International Association for the Study of Lung Cancer (IASLC) cohort
matched for stage of disease with survival as the principal endpoint and local control (local progression
free survival – local PFS) as the secondary endpoint.
Results: Forty-ﬁve reports containing 3771 patients treated with SABR for NSCLC were identiﬁed that ful-
ﬁlled the selection criteria; both survival and staging data were reported in 3171 patients. The 2 year sur-
vival of the 3201 patients with localized stage I NSCLC treated with SABR was 70% (95% CI: 67–72%) with
a 2 year local control of 91% (95% CI: 90–93%). This was compared to a 68% (95% CI: 66–70) 2 year survival
of 2038 stage I patients treated with surgery. There was no survival or local PFS difference with different
radiotherapy technologies used for SABR.
Conclusions: Systematic review of a large cohort of patients with stage I NSCLC treated with SABR sug-
gests that survival outcome in the short and medium term is equivalent to surgery for this population
of patients regardless of co-morbidity. As selection bias cannot be assessed from the published reports
and treatment related morbidity data are limited, a direct comparison between the two treatment
approaches should be a priority. In the meantime, SABR can be offered to stage I patients with NSCLC
as an alternative to surgery.
 2013 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy
and Oncology 109 (2013) 1–7
Open access under CC BY-NC-ND license.Operable non-small cell lung cancer (NSCLC) patients with
resectable disease are currently offered surgical excision as the pri-
mary treatment with or without adjuvant therapy. Patients with
localized (stage T1/2 or AJCC stage I) NSCLC unable to undergo sur-
gery, mostly because of age and/or comorbidity, have been offered
local radiotherapy.
Stereotactic body radiotherapy (SBRT), more recently termed
stereotactic ablative radiotherapy (SABR), is a noninvasive high pre-
cision external beam radiotherapy using focused beams guided by
detailed imaging, to target well-deﬁned small tumors. The ratio-nale for the use of SABR is the assumption that more localized radi-
ation, which spares normal tissue, allows for higher radiation doses
without increasing toxicity with a potential for improved disease
control and survival.
Patients with small localized early stage NSCLC unsuitable for
surgery have been treated with SABR as an alternative to surgery.
It has been suggested that SABR has a potential for achieving dis-
ease control and survival comparable to surgery. This technique
has been the subject of a National Cancer Action Team (NCAT)
report [1] largely focusing on the selection of patients and the tech-
nical aspects of treatment. The report suggested that ‘‘for early
NSCLC . . . the data is sufﬁciently robust for SBRT to be recom-
mended as a routine alternative to other forms of non-surgical
treatment delivered with curative intent’’ although this was largely
2 Systematic review of SABR for NSCLCbased on selected reports with tumor control rather than survival
as the primary endpoint.
In the absence of randomized trials testing the role of SABR
against other treatment options, particularly surgery, we under-
took a systematic review of the current literature to obtain the
most robust evidence possible on the efﬁcacy of SABR. The pub-
lished reports, largely consisting of Phase I/II studies, were assessed
using full systematic review methodology with emphasis on sur-
vival as the primary endpoint. The data were compared to the out-
come of surgery obtained from a matched control population from
the International Association for the Study of Lung Cancer (IASLC)
database [2]. SABR was carried out using a variety of radiotherapy
technologies and this enabled the assessment of potential differ-
ences in outcome for the different treatment platforms.
The incidence of lung cancer in England and Wales is approx-
imately 47 per 100,000 population with the Ofﬁce for
National Statistics reporting a total of 35,000 incident cases in
2008; 78% are non-small cell lung cancers (NSCLC). Approxi-
mately 30% of all NSCLC patients have early stage disease. If SABR
is considered an effective treatment option approximately 10,000
patients in England and Wales could potentially beneﬁt from
SABR per year.Methods
Objective
This systematic review aimed to assess the clinical value of ste-
reotactic body radiotherapy (SABR) in patients with localized
NSCLC on its own and in comparison with surgery and to appraise
the methodological quality of the current clinical evidence.Literature search
Five databases (Embase, Cochrane Library, Medline, Scopus,
Web of Knowledge) were searched using the equivalent search
terms including all terms relating to lung cancer, surgery, radio-
therapy, radiosurgery, SBRT, SABR and others (see search strategy
provided in Supplementary Appendix A). A preliminary literature
search established that the majority of studies and reviews rele-
vant to SBRT had been published from 2006 onward, and therefore
‘2006 to the present’ was taken as the dates of the electronic
search.
The selection criteria for inclusion in the systematic review
were full published articles reporting outcome data from popula-
tions of 20 or more Stage I NSCLC patients treated with SABR with
a median follow up of minimum of 1 year. Reports of conference
proceedings were excluded. No language limits were applied.
Health economic analyses, small size feasibility and technical stud-
ies of SBRT/SABR, repeat publications of the same cohort and arti-
cles reporting outcome data for lesions rather than patients were
excluded (Supplementary Table A1).
The application of the inclusion criteria based on indexed titles
and abstracts of papers was undertaken by one investigator (FS)
and independently validated by two others to a <5% margin of
error.Data extraction and endpoints
Data extraction was carried out independently by two reviewers
(ML and FS) with disagreements resolved by discussion and refer-
ence to the full publications, and to a third reviewer (MB) in the case
of non-agreement. Data were extracted using a piloted electronic
form.Datawere extracted intoﬁve categories (study characteristics)
including study details, participants and their characteristics, inter-
vention, outcomes and non-speciﬁed. The outcome measuresassessed included overall survival (OS), progression-free survival
(PFS), local control (LC), toxicity and quality of life (QOL).
The principal endpoint of the review was the 2 year overall sur-
vival. Where this was not speciﬁcally quoted in the text, it was
estimated from published survival curves. For reliability, two
investigators extracted the survival percentages. Local control at
2 years was obtained using the same methodology.Outcome measures & statistical considerations
The survival ﬁgures in studies reporting other stages of disease
were corrected to reﬂect the expected 2 year OS for stage I disease.
We assumed that the OS can be modeled by a linear combination of
the OS for stage I and stage II disease as used previously [3].
SðtÞobserved ¼ w1S1ðtÞ þw2S2ðtÞ
where w1 is the proportion of patients that are stage I and w2
(=1w1) the proportion of stage II. The validity of this linearity
assumption was conﬁrmed for a cohort of surgically treated early
stage NSCLC patients provided by the IASLC group (Table 2). For
the correction process, we assumed a ratio of deaths at 2 years for
stage I: stage II disease of 0.653. This was based on the IASLC data
for surgically treated early stage NSCLC (Table 2).
Studies without staging data were excluded from the primary
analysis of survival. The corrected survival ﬁgures were illustrated
graphically and were summarized by a weighted average. The sur-
vival data of surgically treated patients were obtained from IASLC
(IASLC group data). Calculation of conﬁdence intervals for the over-
all survival percentage requires a detailed knowledge of the pat-
terns of death and follow-up for all studies; this is beyond the
scope of this report. However, using ﬁgures for median follow-up
and assuming a negative exponential distribution for loss to fol-
low-up, we have obtained approximate 95% conﬁdence intervals.
No comparative local control data were available from the IAS-
LC database for 2 year local control and the ratio of the number of
progressions at the irradiated site for stage I disease compared to
stage II is unknown. In order to correct the local control ﬁgures
to reﬂect a population of stage I patients, we assumed that the pro-
gression ratio at 2 years was the same as the death ratio (0.653).Methodological quality
The following hierarchy of evidence was used to categorize the
evidence relating to SBRT [4].
Level 1:
- Systematic reviews or meta-analyses of randomized con-
trolled trials (RCTs).
- Randomized controlled trials (RCTs).
- Non-randomized controlled trails.
Level 2: Controlled observational studies (e.g., cohort studies,
case control studies).
Level 3: Non-controlled observational studies (e.g., case
studies).
Level 4: Expert opinion based on pathophysiology, bench
research or consensus.
All studies identiﬁed in the review represent Grade 3 evidence: ret-
rospective cohort studies and prospective (Phase I or Phase II)
studies.
Results
2456 SABR articles published between 2006 and June 2012
were identiﬁed, reduced to 756 after duplicates were removed;
83 were reports of SABR treatment for NSCLC which fulﬁlled the
Table 1
NSCLC studies.
Authors No. of
patients
Median age
(years)
Stage
I
Stage
II
Stage
III–IV
Dose (Gy/#) 2 yrs
OS (%)
Expected OS for
stage I (%)
2 yrs
LC (%)
Expected LC for
stage I (%)
Type of
study
Andratschke [14] 92 75 92 24–45/3–5 60 60 83 83 rs
Baumann (1) [15] 141 74 141 30–48/2–4 66 66 Na rs
Baumann (2) [16] 57 75 57 45/3 65 65 Na ps
Beitler [17] 75 71 Na 40/5 (Median) Na Na rs
Bibault [18] 51 68 51 45–60/3 79 79 86 86 rs
Bral [19] 40 73 38 2 60/3–4 52 53 Na ps
Brown [20] 31 Na 31 60–67.5/3–5 84 84 86 86 rc
Champeaux-
Orange [21]
33 70 31 2 40–50/10 Na Na rs
Chen [22] 65 69 54 11 48–64/3.6–8 80 82 Na rs
Coon [23] 26 76 26 60/3 Na Na rs
Dunlap [24] 40 73 40 42–60/3–5 rs
Dunlap T1 27 55 55 90 90
Dunlap T2 13 35 35 70 70
Dworzecki [25] 31 Na 26 5 54–60/3 Na 56 59 rs
Fakiris [26] 70 Na 70 60–66/3 62 62 95b 95 ps
Fritz [27] 40 74 40 30/1 63 63 95 95 ps
Grills [28] 58 78 58 48–60/4–5 72 72 96 96 rs
Guckenberger [29] 40 70 31 9 26–48/1–6 Na Na rs
Hamamoto [30] 128 Na 128 48–60/4–5 Na 96a 87 87 rs
Hof [31] 42 72 38 4 19–30/1 65 67 68 69 rs
Kopek [32] 88 73 87 1 45–67.5/3 49 49 89 89 rs
Koto [33] 31 77 31 45–60/3–8 79 79 Na rs
Le [34] 20 Na 20 15–30/1 64 64 70 70 ps
Matsuo [35] 101 77 101 48/4 80 80 93 93 ps
Nath [36] 50 Na 50 48–52/4–5 52 52 95 95 rs
Ng [37] 20 75 20 45–60/3–5 73 73 95 95 rs
Olsen [38] 130 75 126 4 45–54/3–5 rs
Olsen 54 Gy 111 107 4 63 64 91 91
Olsen 45 Gy 8 8 50 50 50 50
Olsen 50 Gy 11 11 90 90 100 100
Onimaru [39] 41 76 41 40–48/4 64 64 73 73 rs
Onishi [40] 87 74 87 45–72.5/3–10 rs
Onishi 75 Gy 65 65 83 83 Na
Onishi 48 Gy 22 22 79 79 Na
Parashar [41] 23 76 Na 30–60/2–4 Na Na rs
Salazar [42] 60 Na 60 40/4 ps
Salazar (stage Ia) 45 45 81 81 Na
Salazar (stage Ib) 15 15 57 57 Na
Scorsetti [43] 43 75 43 20–32/2–4 53 53 Na rs
Senthi [44] 676 73 676 54–60/3–8 67 67 96 96 rs
Shibamoto [45] 180 77 180 44–52/4 80 80 85 85 ps
Song [46] 32 72.5 32 40–60/3–4 39 39 85 85 rs
Stephans [47] 86 72 86 50–60/3–5 54 54 94 94 rs
Takeda (1) [48] 63 Na 63 50/5 rs
Takeda (1) stage Ia 38 38 90 90 93 93
Takeda (1) stage Ib 25 25 63 63 96 96
Takeda (2) [5] 173 78 101 64 8 40–50/5 rs
Takeda (2) path 115 65 43 7 84 87 90 92
Takeda (2) clin 58 36 21 1 70 75 80 83
Taremi [49] 108 73 mean 108 48–60/3–10 63 63 Na ps
Timmerman [50] 55 72 55 54/3 73 73 Na ps
Trakul [51] 100 Na 91 9 18–60/1–4 Na Na rs
Turzer [52] 36 74 36 45/3 Na Na rs
Vahdat [53] 20 75 20 42–60/3 90 90 95 95 ps
van der Voort van
Zyp [54]
70 76 70 36–60/3 62 62 rs
Van der Voort van
Zyp Schedule 2
10 10 45 /3 78 78
Van der Voort van
Zyp Schedule 3
59 59 60 /3 96 96
Widder [55] 202 76 202 60/3–8 72 72 95 95 ps
Wu [56] 43 69 23 20 34–47.5/4–12 78 82 53 62 rs
Xia [57] 43 71 25 18 50/5 78 82 95 96 ps
Weighted average 70 90
aNa, not available; rs, retrospective study; ps, prospective study.
* Survival data for 52 patients reported in Hamamoto [58].
+ bLocal control data taken from Timmerman [59].
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oligometastases subject to a separate study. Full text of the publi-
cations was reviewed and a further 6 studies were excluded due toinability to extract outcome data for primary analysis. Descriptive
data for each included study with sample size, age, stage, radio-
therapy dose are shown in Table 1.
Table 2
2 year survival for surgically treated early stage NSCLC. (IASLC database).
7th Ed
stage
Total number of
deaths
Total number of
patients
2 year
OS%
95% Conﬁdence
interval
Stage IA 408 792 73 (70,76)
Stage IB 714 1246 64 (62,67)
Stage IIA 293 455 57 (52,61)
Stage IIB 1115 1625 50 (47,52)
Stage I 1122 2038 68 (66,70)
Stage II 1408 2080 51 (49,53)
4 Systematic review of SABR for NSCLCForty-ﬁve reports with a total of 3641 patients were included in
the review (Table 1). Staging information was reported in 44 stud-
ies covering 99% of patients; 86% of patients had stage I disease.
Stage III and IV were excluded from the results except for a total
of 8 patients (Takeda 2012 [5]) which could not be separated out.
Two year survival data were reported in 37 studies covering
3171 (87%) patients. All 2-year survival percentages were cor-
rected to reﬂect the survival probability expected in a population
of stage I patients (Fig. 1). The corrected 2 year OS ranged from
35% to 96% with a weighted average of 70% (95% CI: 67–72%); this
compared to 68% (95% CI: 66–70) in the surgically treated clinical
stage I patients from IASLC data (Table 2). As a robustness check,
the analysis was repeated excluding 1 publications containing
stage III/IV patients (weighted average 69%).
Twenty nine studies representing 2589 (71%) patients reported
2 year local control; 92% of patients were stage I. The 2 year local
control corrected for a population of stage I disease ranged from
50% to 100% (Fig. 2) with a weighted average of 91% (95% CI: 90–
93%). Repeating the analysis without the study involving stage
III/IV patients gave a weighted average of 90%.
Thirty-four of the 45 studies covering 91% of the patients used a
linear accelerator (Linac) and 11 (14%) a robotic mounted linac
(Cyberknife) (Supplementary Figs. 3 & 4). The survival and local
control outcome were analyzed by the equipment used to deliver
SABR (Supplementary Figs. 5 & 6). The weighted average 2 year
OS for Linac patients was 69% (95% CI: 66–71%) compared to 73%Fig. 1. Scattergram of 2 year overall survival corrected to reﬂect a population of stage I
points. The size of each diamond reﬂects the size of the cohort (for individual data poin(95% CI: 61–83%) for patients treated with the robotic mounted
linac and 75% (95% CI: 65–83%) for other technologies (Supplemen-
tary Fig. 5).
The 2 year local control for linac treated patients was 91% (95%
CI: 89–93%) compared to 88% (95% CI: 78–94%) for patients treated
with the robotic mounted linac and 80% (95% CI: 68–91%) for other
technologies (Supplementary Fig. 6).Discussion
With the ability to deliver radiation with higher precision, min-
imizing the dose to normal tissues, a number of techniques have
been developed, described collectively as SBRT or SABR. They are
given as short courses of hypofractionated radiotherapy to doses
beyond conventional radiation tolerance of normal tissue. Such
large doses considered ‘‘ablative’’ to the tumor have been increas-
ingly employed for small targets in the lung, liver and at other sites
and are vying for attention as potential alternative for surgery
[6,7].
In NSCLC SABR has been reserved for patients with potentially
‘‘resectable’’ localized tumors generally considered inoperable lar-
gely due to co-morbidity and the consequent risks of surgery.
SBRT/SABR has been employed in selected patients and while the
reported ‘‘control rate’’ has been high, the effect on survival in
comparison to surgery has not been fully analyzed other than by
using institutional and/or retrospective cohorts treated with sur-
gery. We aimed to provide robust comparative information on
the efﬁcacy of SABR in patients with early stage NSCLC. The results
should provide the most objective comparison that is possible in
absence of randomized studies.
While 2 year local control in patients with stage I NSCLC follow-
ing SABR ranges from 50% to 100%, the weighted mean 2 year con-
trol rate is 91%. Local control has been the principal endpoint used
in the initial studies of SABR, and the high control rate fueled inter-
est in the technique with the perception of highly effective local
treatment. However, local control is not an entirely objective end-
point. It is based on operator assessed imaging, which is com-
pounded by imaging changes due to the high dose radiationNSCLC. The individual studies are distributed along the X axis to avoid overlapping
ts see Table 1).
Fig. 2. Scattergram of 2 year local control corrected to reﬂect a population of stage I NSCLC. The individual studies are distributed along the X axis to avoid overlapping points.
The size of each diamond reﬂects the size of the cohort (for individual data points see Table 1).
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lung lesion does not necessarily equate with functional beneﬁt,
particularly in terms of respiratory function, and the endpoint is
of uncertain clinical importance.
The most objective endpoint in the management of NSCLC is
survival, which is likely to be inﬂuenced not only by the status of
NSCLC but also by the potential adverse effect of treatment and
by co-morbidity; a frequent problem in NSCLC patient populations
that contain a signiﬁcant proportion of smokers and ex-smokers.
The summary 2 year survival probability of the large cohort of
patients with stage I NSCLC treated with SABR is 70% which is com-
parable to survival of a cohort of clinical stage I patients treated
with surgery. It would be of value to assess the efﬁcacy of the treat-
ment modalities for a longer period, especially in early disease
cases. While such data are available for surgery the data for SABR
are not yet sufﬁciently mature to allow such comparisons.
Treatment related toxicity is an important factor in evaluating
therapy, be it invasive surgery or ablative irradiation. The data as
captured in individual studies do not provide for easy comparison
and only survival can be used as an objective comparable endpoint.
This may miss functional consequences of the various treatment
approaches. In this respect a more robust methodology, which pro-
vides for the capture of clinically important functional information,
some of which may be reﬂected in quality of life assessments,
should become an integral part of future evaluation.
The results as presented here were not obtained from a ran-
domized trial and therefore represent highly selected groups of
patients with a considerable risk of bias. It is likely that the SABR
group is biased toward patients with resectable but inoperable dis-
ease, where surgery is technically feasible but considered not
appropriate due to risk of surgery, weighted by patients with more
adverse clinical features. However this cannot be assessed by the
systematic review methodology.
While survival data suggest that SABR is equivalent to surgery
in terms of 2 year survival for patients with stage I NSCLC there
are potential confounding factors which provide some uncertainty.
The surgical group covers an earlier time period with patients diag-
nosed between 1990 and 2000 [2], prior to the general use of SABR.Inevitably such a historical patient group may be affected by ‘‘stage
migration’’, where less common use of intensive staging investiga-
tions such as the routine use of PET [8] and mediastinoscopy in
earlier cohort may have included more advanced stage disease
had more intensive staging been used. In addition, in the earlier
period when the alternative of SABR was not available, more liberal
acceptance of patients for surgery may have also led to inclusion of
patients with less favorable prognoses.
If indeed the patients selected for SABR have adverse prognostic
factors related to co-morbidity that make them ineligible for sur-
gery and stage migration is not considered a confounding factor,
it is possible to argue that the co-morbidity had no adverse effect
on prognosis following SABR and the presumed superiority of sur-
gery in a group of patients with an expected favorable prognostic
proﬁle has not been realized. This may suggest that the potential
selection bias in favor of surgical patients may be negated by some
as yet unidentiﬁed factor associated with the surgical procedure or
the surgical outcome.
In conclusion, it is not possible to exclude patient selection as
the determinant of more adverse prognosis in the surgical series
than would be expected for a more recent stage and co-morbidity
matched surgical cohort. Nevertheless, the available results would
argue in favor of head-to-head comparison of surgery versus SABR
in patients with localized NSCLC considered operable and with a
good prognostic proﬁle.
SABR can be delivered in a number of ways using a conventional
linear accelerator in ﬁxed ﬁeld mode [9] or dynamically with
intensity modulated ﬁxed ﬁeld (intensity modulated radiotherapy
– IMRT) [10] or arcing technique (volumetric arc therapy commer-
cially known as RapidArc or VMAT) [11]. It can also be given using
Tomotherapy (linear accelerator speciﬁcally designed to irradiate
using arc technique) [12] and with a robotic mounted linear accel-
erator (Cyberknife) [13]. The reported results utilized most of the
technological options. Comparing the outcome data for stage I
NSCLC the results appear the same whether employing linear
accelerator, Cyberknife or other technologies. There is, however,
a general perception that as a high precision technique with a need
for technical infrastructure and expertise it is best delivered in
6 Systematic review of SABR for NSCLCdepartments with the appropriate expertise regardless of the tech-
nology employed. In summary, in stage I NSCLC the data do not
suggest beneﬁt in terms of the outcome measures assessed of
one technology over another.
Conclusions
SABR is a technique of localized irradiation suitable for the
treatment of small lesions. On the evidence available the efﬁcacy
of SABR in the treatment of stage I NSCLC is equivalent to surgery
in terms of 2 year survival. The increasing availability of SABR in
radiotherapy departments means that a larger proportion of
patients are likely to be considered for this treatment. Neverthe-
less, a well designed prospective trial assessing all the important
outcome parameters, including treatment related morbidity,
would be of value to provide an objective means of selecting
patients for the appropriate treatment modality.
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